Health Catalyst, Inc. — Form SCHEDULE 13D/A
Filed September 8, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Palogic Value Fund, LP purchased 451,617 shares of Health Catalyst common stock between 8/6/2026 and 9/1/2026 at prices ranging from $1.53 to $1.76 per share, totaling approximately $750k. Concurrently, Palogic Value Management issued a letter to the Board demanding enhanced shareholder disclosures on application revenue, infrastructure migration risks, professional services breakdown, and specific financial/capital allocation frameworks. The letter praised the VitalWare divestiture sale but expressed concern about R&D spending, balance sheet utilization, and management's track record of capital allocation.
Why this rating
Share accumulation (~1.7% of $259M market cap, ~$750k spend) is modest. Letter is activist pressure but prescriptive, not binding. No governance change, contract termination, or material transaction. Routine activist engagement.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.